Correspondence 0001493152-24-033566 from Bone Biologics Corp (BBLG)

Bone Biologics Corp
Date: Aug. 22, 2024 · CIK: 0001419554 · Accession: 0001493152-24-033566

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-281494

Date

August 22, 2024

Author

Bone Biologics Corporation

Form

CORRESP

Company

Bone Biologics Corp

Letter

Bone Biologics Corporation

2 Burlington Woods Drive, Suite 100

Burlington, MA 01803

August 22, 2024

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Robert Augustin

Re:

Bone Biologics Corporation

Registration Statement on Form S-3

File No. 333-281494

Ladies and Gentlemen:

In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Bone Biologics Corporation, a Delaware corporation, hereby requests that the effectiveness of the registration statement on Form S-3 (File No. 333-281494), filed with the U.S. Securities and Exchange Commission on August 12, 2024, be accelerated so that the registration statement becomes effective at 4:00 p.m. Eastern Time on August 26, 2024 or as soon thereafter as practicable.

If you have any questions or comments, please contact Alexander R. McClean of Harter Secrest & Emery at (585) 231-1248.

Very truly yours,
Bone Biologics Corporation

Show Raw Text

CORRESP
1
filename1.htm

Bone Biologics Corporation

2 Burlington Woods Drive, Suite 100

Burlington, MA 01803

August 22, 2024

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Robert Augustin

    Re:

    Bone Biologics Corporation

    Registration Statement on Form S-3

    File No. 333-281494

Ladies and Gentlemen:

In accordance with Rule 461 promulgated
under the Securities Act of 1933, as amended, Bone Biologics Corporation, a Delaware corporation, hereby requests that the effectiveness
of the registration statement on Form S-3 (File No. 333-281494), filed with the U.S. Securities and Exchange Commission on August
12, 2024, be accelerated so that the registration statement becomes effective at 4:00 p.m. Eastern Time on August 26, 2024 or as soon
thereafter as practicable.

If you have any questions or comments,
please contact Alexander R. McClean of Harter Secrest & Emery at (585) 231-1248.

    Very truly yours,

    Bone Biologics Corporation

    By:
    /s/ Jeffrey Frelick

    Jeffrey Frelick

    President and Chief Executive Officer

SecProbe.io